Exclusive: Cannabis Co. Zelira To Begin Clinical Trials For Chronic Pain In Retired Athletes

Global research company Zelira Therapeutics (ASX: ZLD) (OTCQB: ZLDAF) is set to being a cannabinoid-based clinical trial on chronic pain in retired professional and amateur athletes, Benzinga has learned exclusively.

The trial, which could be the first of its kind, was commissioned through a license and management agreement between Zelira and Australian operator Levin Health. Zelira will design and undertake a clinical trial on the efficacy of its proprietary ZTL-106 formulation. Successful results will allow Levin to globally market a clinically-validated formulation targeting chronic pain. 

This is the second clinical trial that …

Full story available on Benzinga.com

More Exclusive: Cannabis Co. Zelira To Begin Clinical Trials For Chronic Pain In Retired Athletes